Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,048 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Clear all
Completed Phase 1 Interventional

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

NCT01307449
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
PNEUMOVAX, Prevnar
Biological
Lead sponsor
Emory University
Other
Eligibility
25 Years to 89 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 23, 2026, 4:17 AM EDT
Completed No phase listed Observational

Immune Responses to COVID-19 Infection or Vaccination

NCT05379478
View directory record Official record
Conditions
COVID-19
Interventions
Laboratory assessment of antibody profiles
Diagnostic Test
Lead sponsor
Aditxt, Inc.
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 23, 2026, 4:17 AM EDT
Completed No phase listed Observational

Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients

NCT04682548
View directory record Official record
Conditions
Multiple Sclerosis, Covid19
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 23, 2026, 4:17 AM EDT
Active, not recruiting Early Phase 1 Interventional

Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors

NCT05035706
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Interventions
Biopsy, Biospecimen Collection, Electronic Health Record Review, Photography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)

NCT00004984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Parenteral Insulin, Close Observation, Oral Insulin, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
711 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2003
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 23, 2026, 4:17 AM EDT
Terminated Phase 1 Interventional

Lenalidomide After Allo Transplant

NCT01750762
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 23, 2026, 4:17 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

NCT06059391
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation Conditioning Regimen, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Pheresis, Placebo Administration, Stem Cell Mobilization Therapy
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

NCT00005780
View directory record Official record
Conditions
Mantle Cell Lymphoma, Lymphoma, Mantle Cell
Interventions
EPOCH-R, GM-CSF, Idiotype vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 23, 2026, 4:17 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

NCT06064279
View directory record Official record
Conditions
Stage IV NSCLC
Interventions
Poly ICLC, IVIG
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

NCT01085318
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rebif
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 23, 2026, 4:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploration of Immunity in Gaucher Disease

NCT01358188
View directory record Official record
Conditions
Gaucher Disease
Interventions
Not listed
Lead sponsor
O & O Alpan LLC
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 23, 2026, 4:17 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

NCT04930055
View directory record Official record
Conditions
Cancer
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2,206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)

NCT01669603
View directory record Official record
Conditions
Common Cold
Interventions
Bifidobacterium lactis Bl-04, Placebo, Rhinovirus
Dietary Supplement · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 60 Years
Enrollment
789 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 23, 2026, 4:17 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States

NCT02153996
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 1 Interventional

NHS-IL12 for Solid Tumors

NCT01417546
View directory record Official record
Conditions
Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant, Malignant Mesenchymal Tumor
Interventions
NHS-IL-12
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

NCT02311361
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
Interventions
Durvalumab, Tremelimumab, Sterostatic body radiation therapy (SBRT)
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 4 Interventional

Long-Term Lamivudine Therapy for Chronic Hepatitis B

NCT00120354
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Immune Response to Heplisav in Healthy Older Adults

NCT01999699
View directory record Official record
Conditions
Hepatitis B
Interventions
HEPLISAV
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
50 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 23, 2026, 4:17 AM EDT
Completed No phase listed Observational

CNS (Central Nervous System) Viral Dynamics and Cellular Immunity During AIDS

NCT00583167
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

NCT00308412
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rHPIV3cp45, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 36 Months
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2010 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT05412030
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
AFX3772, Prevnar 13, Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
42 Days to 90 Days
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
48
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 23, 2026, 4:17 AM EDT
Completed Phase 3 Interventional Results available

Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults

NCT04362176
View directory record Official record
Conditions
COVID-19, Coronavirus, SARS-CoV-2
Interventions
pathogen reduced SARS-CoV-2 convalescent plasma, Placebo
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 23, 2026, 4:17 AM EDT